The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Balagula, Yevgeniy; Rosen, Steven T.; Lacouture, Mario E.

doi:10.1016/j.jaad.2010.06.051

Cited by 81 publications

(70 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Papulopustular acne-like eruption is the most common cutaneous adverse event (5) with an incidence rate of 55% (1). Xerosis, pruritus, desquamation, eczematous eruptions, teleangectasia, hyperpigmentation, trichomegalia, alopecia and nail alterations have also been reported (6)(7)(8). The present case report describes an atypical skin reaction in a patient treated with gefitinib.…”

Section: Introductionmentioning

confidence: 85%

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Ferrazzi

Russo

Pasello

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne-like eruption. Cutaneous toxicities can affect treatment compliance and the quality of life of the patient. The present study reports a case of gefitinib-induced atypical skin reaction in a 73-year-old woman with advanced non-small cell lung cancer, who developed a squamous-crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. The patient was treated with 100 mg minocyclin (2 tablets/day, orally) and with ryfamicin topically. A complete resolution of the lesions was observed 2 weeks later. The present case report explored the pathogenesis of this skin manifestation, focusing on the underlying immunological mechanisms. A review of the literature concerning skin reactions to gefitinib was also conducted.

show abstract

Section: Introductionmentioning

confidence: 85%

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Ferrazzi

Russo

Pasello

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…4,[17][18][19] It is a disorder characterized ''by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet.'' 7 It has grades 1 to 3, based on the severity of the skin changes and the effect on performing ADLs.…”

Section: Palmar-plantar Erythrodysesthesia Syndromementioning

confidence: 99%

“…The spectrum of dermatologic AEs from cancer treatments has a profound impact on physical, 2 emotional, 3 financial, and psychosocial well-being of patients. 4 Consequently, assessment and management of dermatologic AEs have become an essential part of the care of patients with cancer, requiring close collaboration between oncologists and dermatologists. This partnership requires uniform cataloging and grading of AEs for effective communication, better delivery of interventions, and appropriate supportive measures.…”

mentioning

confidence: 99%

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Chen

Setser

Anadkat

et al. 2012

Journal of the American Academy of Dermatology

Self Cite

258

211

View full text Add to dashboard Cite

“…In anticancer chemotherapy, the risk of potential side effects is one of the important features (Macdonald et al 2015;Balagula et al 2011). In the case of paclitaxel, a known side effects include leukopenia, thrombocytopenia, anemia, muscle pain, and hair loss symptoms.…”

Section: Introductionmentioning

confidence: 99%

Epigallocatechin-3-gallate inhibits paclitaxel-induced apoptosis through the alteration of microRNA expression in human dermal papilla cells

Shin

Jun

Kim³

et al. 2018

biomed dermatol

View full text Add to dashboard Cite

Background: Paclitaxel well known as anti-cancer drug has been shown to cause alopecia in chemotherapy. The paclitaxel chemotherapy-mediated alopecia is induced by apoptotic damage in human dermal papilla (HDP) cells. Epigallocatechin-3-gallate (EGCG) inhibits apoptosis against anti-cancer drug such as cisplatin. EGCG, one of the green tea extract ingredients, has been reported to enhance cell viability and to inhibit apoptosis. However, it is unclear that EGCG enhances cell viability and inhibits apoptosis against paclitaxel-induced apoptotic damage in HDP cells. Methods: We show cell viability, cell cycle, and microRNA (miRNA) expression in EGCG-mediated rescue cell to paclitaxel-mediated cell death and growth arrest. Results: EGCG promotes cell survival and cell death inhibitory effects and alteration of miRNA expression in paclitaxelexposed HDP cells were investigated. Firstly, paclitaxel increases apoptosis and EGCG promotes cell survival and represses paclitaxel-induced apoptosis in a dose-dependent manner. Fluorescence-activated cell sorting (FACS) analysis showed that EGCG protects apoptosis in paclitaxel-exposed HDP cells. miRNA microarray analysis was performed and 48 miRNAs changed by EGCG in paclitaxel-exposed HDP cells were identified. In gene ontology analysis in silico, miRNAs regulate apoptosis and cell proliferation-regulated genes, such as BCL2L1, BCL2L2, BBC3, and MDM2. In Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, miRNAs are related to mitogen-activated protein kinase (MAPK) signaling pathway and Wnt signaling pathway, which regulate apoptosis and cell proliferation. Conclusions: EGCG inhibits apoptosis through regulating miRNA expression related to apoptosis and cell proliferation in paclitaxel-treated HDP cells.

show abstract

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Cited by 81 publications

References 88 publications

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Epigallocatechin-3-gallate inhibits paclitaxel-induced apoptosis through the alteration of microRNA expression in human dermal papilla cells

Contact Info

Product

Resources

About